By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD#38–Francisco Gonzalez-Lima, Ph.D.: Alzheimer’s disease & the vascular hypothesis
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
CHAPTERS
- 0:04 – 10:09
Francisco's Background and Functional Brain Mapping
After the host's intro, Francisco Gonzalez-Lima describes his path as a behavioral neuroscientist at UT Austin. He covers his early training, the fluorodeoxyglucose method that led to FDG PET, and why functional imaging can detect disease before structural change.
- •27 years as a tenured professor in Austin
- •Work in Germany on the FDG autoradiographic method that led to FDG PET
- •Functional techniques reveal disease before structural changes
- •Early interest in animals and a brain dissection at Tulane sparked his focus on the brain
- 10:09 – 24:36
Brain Circuitry, Redundancy and Parallel Processing
The two compare organs as different kinds of engineers and discuss why the brain is a redundant parallel computing system. Francisco explains convergence and hierarchical processing from spinal reflexes to the cortex.
- •Heart as mechanical engineer, brain as electrical engineer, liver as chemical engineer
- •Brain is a redundant, parallel system using convergence, like NASA's redundant computers
- •Hierarchy runs from spinal reflex to midbrain to thalamus and cortex
- •The cortex mainly inhibits behavior and selectively releases movement
- •Most neurodegenerative disease, except Parkinson's, targets the cortex
- 24:36 – 41:36
Why the Amyloid Hypothesis Fails: Early vs. Late Onset Disease
Peter notes the lack of progress on Alzheimer's and asks about the conventional explanation. Francisco calls it the field's biggest failure and traces it to the 1907 case and the early historical rivalry. He argues early-onset and late-onset dementia are different diseases and that amyloid does not track cognitive impairment.
- •Alois Alzheimer's 1907 case was a young patient, not typical late-onset dementia
- •Fischer's earlier work on senile dementia was sidelined by Kraepelin's textbook
- •Nine in ten cases have no familial component
- •Transgenic mice showed brain abnormalities before amyloid deposition
- •Cognitively normal brains and Alzheimer's brains can be indistinguishable on amyloid and tangles
- 41:36 – 47:56
Hypometabolism and the Posterior Cingulate Memory Circuit
The discussion turns to the hypometabolism seen across imaging methods and where it appears first. Francisco explains the Papez circuit and how disruption anywhere in it causes memory disease.
- •FDG PET, blood flow and ASL imaging all show hypometabolism, including in mild cognitive impairment
- •Earliest hypometabolism is in the posterior cingulate cortex, which feeds the entorhinal cortex and hippocampus
- •Papez circuit links cingulate, entorhinal, hippocampus, mammillary bodies and thalamus
- •Damage anywhere in it, such as thiamine deficiency in Korsakoff, produces memory problems
- 47:56 – 54:11
Working Memory, Early Decline and Where to Intervene
Francisco describes memory stages and says the earliest deficit is in prefrontal working memory, an anterograde problem. They discuss how hard it is to separate normal aging from pathology and why he targets the prefrontal cortex.
- •Immediate memory holds about seven items and its transfer depends on the prefrontal cortex
- •Retrograde problems come later when the limbic circuit is engaged
- •Patients notice anterograde deficits before families notice retrograde ones
- •Mild cognitive impairment is hard to define; comparing to one's own history helps
- •His approach is to intervene in the prefrontal central executive network early
- 54:11 – 1:08:56
The Vascular Hypothesis: Chronic Cerebral Hypoperfusion
Peter summarizes the revised view of late-onset dementia, and Francisco describes chronic hypoperfusion as the original, vascular hypothesis. They discuss arterial stiffening, autoregulation, blood pressure, and how this slow process differs from stroke.
- •Blood supply to the brain falls about 20% between ages 22 and 60
- •Carotid intima-media thickness relates linearly to cognitive decline
- •Autoregulation compensates but higher pressure damages capillaries and endothelium
- •Heart failure can also cause hypoperfusion
- •Chronic hypoperfusion differs from the acute event of a stroke
- 1:08:56 – 1:18:23
Mitochondrial Respiration and Cytochrome Oxidase
Francisco explains that oxygen delivery matters because of cytochrome c oxidase in the electron transport chain. They review how electron donors, proton gradients and ATP production work, and why complex four is central.
- •Cytochrome oxidase reduces oxygen to water and is the rate-limiting enzyme
- •Electron donors NADH and FADH enter at complexes one and two
- •Proton flow through complex five drives ATP synthesis
- •All aerobic organisms rely on cytochrome oxidase
- •Poor oxygen supply leaves the brain energy-starved regardless of food intake
- 1:18:23 – 1:33:55
Inducible Cytochrome Oxidase Inhibition in the Alzheimer's Brain
Francisco explains that complex four is highly inducible, falls quickly with ischemia and can recover. His fresh-frozen Alzheimer's brains showed the enzyme inhibited, and animal models with partial occlusion or sodium azide reproduce memory deficits without gross changes.
- •Cytochrome oxidase is a 13-subunit enzyme regulated on demand
- •In Alzheimer's brains the enzyme was inhibited rather than reduced in amount
- •Partial occlusion or low-dose azide gives cognitive deficits in animals
- •Amyloid is described as compensatory, with cytochrome c release signaling cell death
- •Brain energy demand and lack of anaerobic escape make it vulnerable
- 1:33:55 – 1:38:42
Risk Factors, Head Trauma and a Common Mitochondrial Denominator
Peter asks about mitophagy, and Francisco says that by then it is too late and the focus should be intervention earlier. They discuss atherosclerosis and head trauma as risk factors and the shared mitochondrial denominator across dementias.
- •Once energy machinery is compromised, clearing damaged mitochondria is too late
- •Atherosclerosis in large vessels is an important risk factor
- •Repeated head trauma resembles the vascular and metabolic problem
- •Dementia pugilistica is often confused with Alzheimer's and Parkinson's
- •Facilitating mitochondrial respiration could help despite hypoperfusion
- 1:38:42 – 1:51:11
Methylene Blue: Ehrlich's Magic Bullet and Its History
Francisco introduces methylene blue as a metabolic enhancer that acts as an electron cycler at low doses. They cover Paul Ehrlich's discovery, hormetic dosing, redox color changes, and uses for malaria and bladder infections.
- •At low doses methylene blue bypasses blocked complexes; at high doses it is toxic
- •Ehrlich found it stained nervous tissue and coined 'magic bullet'
- •The biphasic or hormetic dose response and the leuco form
- •Historic uses include urinary infections and malaria
- •Chlorpromazine derived from methylene blue chemistry
- 1:51:11 – 2:05:58
Regulatory Status, Purity and the LMTM Trial
They discuss why methylene blue is grandfathered with no commercial sponsor, and the purity grades Francisco warns about. They then examine the LMTM trial, TauRx's anti-tau framing, and criticism of the standard cholinesterase inhibitors and memantine.
- •Grandfathered status and lack of patent mean little commercial incentive
- •Laboratory and industrial grades contain toxic impurities
- •LMTM is a reduced methylene blue developed with an anti-tau hypothesis
- •Francisco thinks background drugs may have obscured the trial results
- •He calls cholinesterase inhibitors and memantine ineffective
- 2:05:58 – 2:13:59
Near-Infrared Light to Boost Cytochrome Oxidase
Francisco describes transcranial near-infrared laser light, around 1064 nm, that photo-oxidizes cytochrome oxidase. They discuss safety, penetration, why it is not combined with methylene blue, and oral versus intravenous methylene blue.
- •Near-infrared photons are absorbed by cytochrome oxidase
- •1064 nm avoids hemoglobin absorption and penetrates tissue
- •Only 1–2% reaches the cortex surface, so effect is localized to gray matter
- •Methylene blue and light are kept separate because methylene blue interacts with photons
- •Oral dosing is slower and safer than intravenous
- 2:13:59 – 2:25:29
Prevention Through Ketones, Fasting and Metabolic Strategies
Peter asks what is specific to brain prevention, and Francisco points to ketogenic diet and ketones, since glucose uptake declines with age while ketone uptake does not. They discuss insulin resistance, fasting, and the three approaches he envisions.
- •Brain glucose transport declines with aging, but ketone uptake is preserved
- •Exogenous ketones may substitute for a ketogenic diet, to be resolved empirically
- •Infants rely on ketones from medium-chain triglycerides in milk
- •Obese people have downregulated ketogenic enzymes; Francisco fasts weekly
- •Three approaches: metabolic pharmacology, near-infrared light and diet
- 2:25:29 – 2:32:08
Research Funding, Trauma Applications and the Case for Methylene Blue Trials
Francisco describes grants for devices measuring oxidized cytochrome oxidase in humans and trials of near-infrared light. Peter proposes methylene blue for traumatic brain injury, and Francisco discusses its neuroprotective results, the funding barrier from the lack of patent profit, and his human fMRI memory study.
- •Devices measure oxidized cytochrome oxidase in the living human brain
- •Grants support NIH BRAIN Initiative work and a National Institute on Aging study of mild cognitive impairment
- •Methylene blue rescued stroke damage in animal models at about 1 mg/kg
- •Lack of patentability discourages pharma and NIH investment
- •Human fMRI study showed improved memory retrieval after acute methylene blue
